Cytokinetics ACACIA-HCM and MAPLE-HCM Late-Breaking Additional Analyses Published in Circulation and JACC Heart Failure at ESC 2026
Cytokinetics (NASDAQ: CYTK) presented Saturday August 29, 2026 additional results from the Phase 3 ACACIA-HCM (Myqorzo aficamten for non-obstructive HCM) and MAPLE-HCM trials in a Late-Breaking Clinical Trial Session at ESC Congress 2026 Munich, with simultaneous publications in Circulation and Journal of the American College of Cardiology: Heart Failure. The ACACIA-HCM additional analyses examined improvements in cardiac structure and diastolic function in patients with non-obstructive HCM (LV mass reduction, LV wall thickness reduction, and LA volume reduction versus placebo at Week 36), extending the primary readout (KCCQ Clinical Summary Score and peak VO2) presented in the Hot Line Session Friday August 28 and simultaneously published in NEJM. The follow-up data strengthens the aficamten commercial case for supplemental NDA in Q4 2026 and continues to differentiate the cardiac myosin inhibitor mechanism from mavacamten (Camzyos, Bristol Myers Squibb) which is currently approved only for obstructive HCM.